Chimerix Inc

NASDAQ:CMRXUnited States

Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Contact Information

Headquarters

2505 Meridian Parkway, Suite 100DURHAM, NC, United States 27713

Phone

919-806-1074

Fax

919-806-1146

Executives

Chairman of the Board

Michael Sherman

President, Chief Executive Officer, Director

Michael Andriole

Chief Financial Officer

Michelle LaSpaluto

Chief Operating Officer, Chief Commercial Officer

Thomas Riga

Chief Medical Officer

Allen Melemed